Structure of important neurotransmitter regulator determinedFebruary 04, 2008Blacksburg, Va. - Researchers from Virginia Tech and the Brookhaven National Laboratory have solved the structure of an enzyme that is critical in the regulation of the neurotransmitter system in the human brain. The enzyme is human kynurenine aminotransferase II (KAT II), which regulates the activity of the neurotransmitter system that is activated by glutamate, the most common neurotransmitter in the brain. Qian Han, a research scientists in biochemistry at Virginia Tech; Howard Robinson, a biologist at Brookhaven; and Jianyong Li, associate professor of biochemistry at Virginia Tech, report their findings in the article, "Crystal structure of human kynurenine aminotransferase II," in the Feb. 8 issue of the Journal of Biological Chemistry (www.jbc.org/). Li, who is corresponding author, explained that learning and memory depend upon glutamate; however, over stimulation will lead to neuron death and is one cause of such neurodegenerative diseases Parkinson's and Alzheimer's. "The product of KAT II is kynurenic acid (KA) that is a noncompeting binder of the glutamate receptors. Its binding to the glutamate receptors reduces stimulation. So it (KA) has a regulatory effect," Li said. "It is considered protective - although too much is also a problem," he said. Before scientists can target KAT II as a treatment, they have to know how it works. Part of the challenge was solved when the DNA sequence of KAT II was determined, but knowing the code is not enough. How proteins pass their critical messages also depends upon their shape. Imagine proteins as curls of ribbons with each unique fold as important to the messages they convey as the sequences of letters in their genetic code. Han, Robinson, and Li succeeded in determining both the unbound protein and its complex three-dimensional structures of KAT II. The structure in complex with kynurenine reveals the almost ephemeral linkages of the KAT II enzyme with its substrate. "Now we know what it looks like, we can determine how it works and do research into how to manipulate the protein," Li said. "We have provided a molecular basis for biochemical regulation of this critical regulator." The article reports on Han's research to crystallize KAT II in combination with a substrate. Robinson used a synchrotron to create X-ray diffraction patterns to reveal atomic and molecular associations within the crystal, which allowed Han and Li to do phase determination and an iterative process of model building and refinement and eventually describe the structure. Virginia Tech |
|||||||||||||||||||||
| Related Neurotransmitter Current Events and Neurotransmitter News Articles Researchers begin to decipher metabolism of sexual assault drug It's a naturally occurring brain chemical with an unwieldy name: 4-hydroxybutyrate (4-HB). Taken by mouth, it can be abused or used as a date-rape drug. New Down syndrome treatment suggested by Stanford/Packard study in mice At birth, children with Down syndrome aren't developmentally delayed. But as they age, these kids fall behind. Memory deficits inherent in Down syndrome hinder learning, making it hard for the brain to collect experiences needed for normal cognitive development. Cognitive dysfunction reversed in mouse model of Down syndrome A study by neuroscientist William C. Mobley, MD, PhD, chair of the Department of Neurosciences at the University of California, San Diego School of Medicine, and colleagues at Stanford University Medical School has demonstrated a possible new approach to slowing the inevitable progression of cognitive decline found in Down's syndrome. CSHL team solves structure of NMDA receptor unit that could be drug target for neurological diseases A team of scientists at Cold Spring Harbor Laboratory (CSHL) reports on Thursday their success in solving the molecular structure of a key portion of a cellular receptor implicated in Alzheimer's, Parkinson's, and other serious illnesses. Mood improves on low-fat, but not low-carb, diet plan After one year, a low-calorie, low-fat diet appears more beneficial to dieters' mood than a low-carbohydrate plan with the same number of calories. BUSM researchers show dieters can experience neurobiological similarities of drug addicts Researchers from Boston University School of Medicine (BUSM) have shown that intermittent access to foods rich in fat and sugar induces changes in the brain which are comparable to those observed in drug dependence. Scripps team shows diet switching can activate brain's stress system, lead to 'withdrawal' symptoms In research that sheds light on the perils of yo-yo dieting and repeated bouts of sugar-bingeing, researchers from The Scripps Research Institute have shown in animal models that cycling between periods of eating sweet and regular-tasting food can activate the brain's stress system and generate overeating, anxiety, and withdrawal-like symptoms. Widely used cholesterol-lowering drug may prevent progression Simvastatin, a commonly used, cholesterol-lowering drug, may prevent Parkinson's disease from progressing further. Neurological researchers at Rush University Medical Center conducted a study examining the use of the FDA-approved medication in mice with Parkinson's disease and found that the drug successfully reverses the biochemical, cellular and anatomical changes caused by the disease. Benefit of memantine in the treatment of Alzheimer's disease not proven There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine. Changes in brain chemicals mark shifts in infant learning When do you first leave the nest? Early in development infants of many species experience important transitions-such as learning when to leave the protective presence of their mother to start exploring the wider world. More Neurotransmitter Current Events and Neurotransmitter News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||